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Eph receptors constitute the largest family of receptor tyrosine kinases in the human genome. EphA2 is one prominent member that
is overexpressed and functionally altered in many invasive cancers, including pancreatic cancer. Dasatinib, which is a multi-targeted
kinase inhibitor mainly developed for Bcr-Abl and Src family kinases, has recently been shown to have significant activity against
EphA2. As selective small molecule EphA2 inhibitors are not currently available, we investigated the therapeutic potential to target
EphA2 by dasatinib in pancreatic cancer cell lines. Using in vitro kinase assays, we found that EphA2 receptor tyrosine kinase was
inhibited directly by dasatinib in a dose-dependent manner. Stimulation with ephrinA1 produced rapid increases of EphA2
phosphorylation that were inhibited by dasatinib, although the effects on activation of downstream signalling differed among the
pancreatic cancer cell lines. Dasatinib also inhibited ligand-induced binding of EphA2 to the ubiquitin ligase Cbl, and the internalisation
and degradation of EphA2, suggesting that these processes are dependent on kinase activity. Treatment with dasatinib decreased
EphA2 phosphorylation in BxPC-3 xenografts, suggesting that dasatinib might have activity in pancreatic cancer due to EphA2
inhibition, besides its effects on Src.
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The Eph family of receptor tyrosine kinases (RTKs), with at least
14 distinct members in mammals, constitutes the largest subfamily
of RTKs (Pasquale, 2004). Eph RTKs are divided into two
subclasses (EphA and EphB) based on sequence similarity and
their preferential binding to ligands, which are tethered to the cell
surface either by a glycosylphosphatidylinositol-anchor (ephrinA)
or by a single transmembrane domain (Kullander and Klein, 2002).
Upon ligand binding, Eph receptors multimerise and become
phosphorylated (Dodelet and Pasquale, 2000). Eph RTKs are
increasingly understood to have significant functions in disease
and development (Zantek et al, 1999). In normal development, Eph
receptors frequently control the compartmentalisation of cells in
complex tissues such as the vascular system, brain and intestinal
epithelium, through their ability to mediate cellular repulsion and
adhesion. In tumourigenesis, they have been implicated in cellular
transformation, metastasis and angiogenesis (Nakamoto and
Bergemann, 2002). For example, B type receptors appear to
suppress the invasiveness of colon cancer cells (Batlle et al,
2005), whereas A type receptors such as EphA2 may have a
pro-oncogenic effect.
EphA2 critically controls many aspects of cell behaviour (Kinch
and Carles-Kinch, 2003). Epithelial cells normally form stable
linkages with adjacent cells, and express low levels of EphA2
that are enriched within intercellular junctions (Zantek et al, 1999).
This localisation favours stable ligand binding, and indeed, EphA2
on normal epithelial cells is autophosphorylated (Zantek et al,
1999; Miao et al, 2001). In contrast, malignant cells generally show
unstable cell–cell contacts (Kinch and Burridge, 1995), and a
consequence of this change is that the high levels of EphA2 on
malignant cells fail to bind ligand and thus become diffusely
distributed over the cell surface (Zantek et al, 1999; Macrae et al,
2005). Thus, EphA2 function can be altered in malignant cells (Kinch
and Carles-Kinch, 2003). EphA2 is also frequently overexpressed and
functionally altered in many invasive cancers (Walker-Daniels et al,
2003). For example, high levels of EphA2 have been documented in
metastatic melanoma, as well as cancers of the mammary gland,
cervix, ovary, prostate, colon, lung, kidney, esophagus and pancreas
(Easty et al,1 9 9 5 ;O g a w aet al, 2000; Zantek et al, 2001; Zelinski et al,
2001; Nakamoto and Bergemann, 2002; Kinch et al,2 0 0 3 ;M i y a z a k i
et al, 2003; Ireton and Chen, 2005; Mudali et al, 2006).
However, despite the strong correlation of EphA2 receptor
expression with malignant phenotypes, the mechanisms by which
EphA2 contributes to tumour cell malignancy are far from clear
(Fang et al, 2005). Some evidence supports the idea that EphA2
receptor phosphorylation is not necessary to confer kinase activity
and tumorigenicity (Zantek et al, 1999; Walker-Daniels et al,
2002), or is even tumour suppressive (Guo et al, 2006). Other data
Revised 21 August 2008; accepted 25 August 2008; published online
16 September 2008
*Correspondence: Dr DW Hedley, Department of Medical Oncology
and Hematology, Ontario Cancer Institute/Princess Margaret Hospital,
610, University Avenue, Toronto, Ontario, Canada M5G 2M9;
E-mail: david.hedley@uhn.on.ca
British Journal of Cancer (2008) 99, 1074–1082
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssuggest that EphA2 receptor phosphorylation may be important in
conferring the oncogenic potential (Ogawa et al, 2000; Brantley
et al, 2002; Dobrzanski et al, 2004). Hence, EphA2 represents a
therapeutic target for novel anticancer agents.
Dasatinib is an oral dual Bcr/Abl and Src family kinases
inhibitor, approved for use in patients with chronic myelogenous
leukaemia and currently tested as an Src inhibitor (Talpaz et al,
2006). In a recent report, Huang et al (Huang et al, 2007) showed
that EphA2 was highly expressed in dasatinib-sensitive cell lines
and that EphA2 was also inhibited by dasatinib. Furthermore,
EphA2 and several other members of Eph RTKs have been shown
as targets of dasatinib by gene expression and a chemical
proteomic profiling approach (Bantscheff et al, 2007; Rix et al,
2007; Wang et al, 2007). As EphA2 is frequently overexpressed in
pancreatic cancer (Duxbury et al, 2004; Mudali et al, 2006), and
selective small molecule EphA2 inhibitors are not currently
available, we investigated the therapeutic potential to target EphA2
by dasatinib in several pancreatic cancer cell lines as well as in
BxPC-3 xenografts.
MATERIALS AND METHODS
Cell lines
The human pancreatic cancer cell lines BxPC-3, PANC-1, MIA
PaCa-2 and human embryonic kidney (HEK) 293 cell line were
obtained from American Type Culture Collection (Manassas, VA,
USA). BxPC-3 was grown in RPMI-1640 with 10% fetal bovine
serum (FBS). PANC-1 was grown in Dulbecco’s modified Eagle’s
medium (DMEM)-H21 with 10% FBS. MIA PaCa-2 was grown in
DMEM-H21 with 10% FBS and 2.5% horse serum. HEK-293 was
grown in DMEM with 10% FBS. Cells were maintained at 371C
under standard cell culture conditions.
Reagents and antibodies
Mouse monoclonal antibodies against phosphotyrosine
(P-Tyr-100), phospho-STAT3 (Tyr705) as well as rabbit polyclonal
antibodies against phospho-Src (Tyr416), phospho-FAK (Tyr576/
577), phospho-FAK (Tyr925), phospho-Akt (Ser473), phospho-
Paxillin (Tyr118), phospho-p44/42 MAPK (Thr202/Tyr204) and
antibodies directed against their nonphosphorylated counterparts,
were purchased from Cell Signaling Technology (Beverly, MA,
USA). Mouse monoclonal antibody against phospho-STAT3
(Ser727) was from BD Biosciences (Mississauga, Ontario, Canada).
Rabbit polyclonal antibodies directed against EphA2 and Cbl
were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA). A mouse monoclonal antibody against EphA2 and
recombinant mouse ephrin-A1/Fc chimera were from R&D
Systems Inc. (Minneapolis, MN, USA). The secondary antibodies
for western blots (anti-mouse and anti-rabbit IgG antibodies) were
from Amersham Biosciences (Buckinghamshire, United Kingdom).
Protein G-Sepharose was from Sigma-Aldrich Canada Ltd.
(Oakville, Ontario, Canada). AffiniPure goat anti-human IgG, Fcg
fragment-specific was from Jackson ImmunoResearch laboratories
Inc. (West Grove, PA, USA). [g-
32P]ATP was from New England
Nuclear (Boston, MA, USA).
Drug preparation
Dasatinib was purchased from Toronto Research Chemicals
(North York, Ontario, Canada). PP2 was purchased from
Calbiochem (San Diego, CA, USA). Dasatinib and PP2 used for
tissue culture were both dissolved in DMSO, aliquoted, and stored
at appropriate temperature. Dasatinib was prepared freshly as a
12.5mgml
1 suspension in 80mM sodium citrate/citric acid buffer,
pH 3.0 for oral gavage in vivo.
In vitro kinase assays
In vitro autophosphorylation assays were essentially performed as
described earlier (Holland et al, 1997). HEK-293 cells were transfected
with cDNA-encoding human EphA2 or human EphB2. Cells were lyzed
20h later and EphA2 or EphB2 was immunoprecipitated. Immuno-
precipitated EphA2 or EphB2 was washed in lysis buffer [50mmoll
1
HEPES (pH 7.5), 10% glycerol, 1% Triton X-100, 150mmoll
1 NaCl,
1mmoll
1 EGTA, 1.5mmoll
1 MgCl2,1 0 0m m o ll
1 NaF, 10mmoll
1
Na4P2O710H2O, 1mmoll
1 Na3VO4] and kinase reaction buffer,
incubated with dasatinib (0, 20, 100 and 200nM,f i n a lD M S O
concentration 0.05% in all reactions) at room temperature for
10min and then incubated with 10mCi of [g-
32P]ATP at room
temperature for 30min. The reactions were terminated by the addition
of 6Laemmli sample buffer and boiling. After resolving samples
b y1 0 %S D S–P A G E ,t h eg e lw a ss t a i n e dw i t hC o o m a s s i eb l u et oc h e c k
for equal loading, then dried and exposed.
Cell proliferation assay
BxPC-3, PANC-1 and MIA PaCa-2 cells were cultured in 96-well
plates at 5000 cells per well in 100ml complete medium and then
pretreated with 0, 25, 50, 100 and 200nM dasatinib for 48h.
According to the manufacturer’s instructions, viable cell number
was determined using a colorimetric method based on the cellular
reduction of the tetrazolium compound 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) into a soluble coloured formazan product (CellTiter 96
Aqueous One Solution Cell Proliferation Assay, Promega Corp.,
Madison, WI, USA).
Cell cycle analysis
Subconfluent BxPC-3, PANC-1 and MIA PaCa-2 cells were treated
with 0, 25, 50, 100 and 200nM dasatinib for 24h, and then
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20
200
100
0 0
20
200
100
A
u
t
o
r
a
d
i
o
g
r
a
p
h
A
u
t
o
r
a
d
i
o
g
r
a
p
h
IP:IgG IP:anti-EphA2 IP:IgG IP:anti-EphB2
EphB2 EphA2
A
B
Figure 1 EphA2 receptor tyrosine kinase activity is inhibited directly by
dasatinib. HEK-293 cell lysates transfected with EphA2 or EphB2 constructs
were immunoprecipitated with anti-EphA2 or anti-EphB2 antibody and
kinase assays were performed in the presence of increasing amounts of
dasatinib. Inclusion of dasatinib resulted in decreased autophosphorylation.
The same gel was exposed for 5h (A) and then exposed for 20h (B).
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spermeabilised with Triton X-100, treated with ribonuclease, and
stained with 50mgml
1 propidium iodide. DNA histograms were
analysed using ModFit LTt (Verity, Topsham, ME, USA).
Ligand stimulation, immunoblotting and
immunoprecipitation
Cells in logarithmic growth phase were serum-starved (0.5%
serum) overnight, stimulated with preclustered 2mgml
1 ephrin
A1-Fc for the indicated times and then processed for immunoblot-
ting and immunoprecipitation. Briefly, cells were washed with ice-
cold PBS and lysed in lysis buffer containing protease inhibitor
cocktail tablets (Roche Diagnostics, Laval, Quebec, Canada) for 1h
on ice. Equivalent amounts of protein (assayed with bicinchoninic
acid protein assay from Pierce Biotechnology Inc., Rockford, IL,
USA) were separated on 10% SDS–PAGE gels. Proteins were
transferred to polyvinylidene difluoride membranes (Millipore,
Bedford, MA, USA) and probed with the appropriate antibodies
according to the manufacturer’s instructions. For immunopreci-
pitation, EphA2 or Cbl was immunoprecipitated from 200–500mg
cleared lysates using anti-EphA2 or Cbl antibody plus protein
G-Sepharose. Products were fractionated as above and blots
probed with anti-phosphotyrosine or anti-EphA2 antibody.
Blots were stripped and re-probed with anti-EphA2 or anti-Cbl
antibody. Detection was conducted using SuperSignal West
Pico chemiluminescent substrate kits (Pierce Biotechnology Inc.,
Rockford, IL, USA) or enhanced chemoluminescence Plus
detection reagents (GE Healthcare, Piscataway, NJ, USA).
Immunofluorescence microscopy
Cells were grown on glass chamber slides coated with colla-
gen (125mgml
1, BD Biosciences, Mississauga, Ontario, Canada).
For staining, cells were fixed with PBS containing 4% paraformal-
dehyde for 15min at room temperature, permeabilised with 0.2%
Triton X-100, then blocked with PBS containing 10% FBS. After
blocking, cells were incubated with diluted monoclonal antibody
overnight at 41C followed by Cy3-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch, West Grove, PA, USA) at room
temperature in the dark for 1h. Control experiments with
secondary antibody alone were performed to confirm the absence
of background staining. Between each step, cells were washed
with PBS. After final washes, slides were coverslipped with
Vectashield Mounting Medium with DAPI and examined by
confocal microscopy.
BxPC-3 xenografts
Animal experiments were done in the animal facility of the
Princess Margaret Hospital, operated under the guidelines
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Figure 2 In vitro anti-tumour activity of dasatinib. BxPC-3, PANC-1 and MIA PaCa-2 cells were pretreated with 0, 25, 50, 100 and 200nM dasatinib for 24
or 48h. (A) Effects of 48h treatment with dasatinib on the in vitro growth of BxPC-3, PANC-1 and MIA PaCa-2 cells at the indicated concentrations were
measured by MTS assay. *Statistically significant from control (Po0.05). (B) Single parameter DNA histograms showed the cell cycle effects of 24h
treatment with dasatinib at the indicated concentrations. Percent cells in G1-S-G2/M phase are given. CV, coefficient of variation.
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sapproved by the Canadian Council for Animal Care. BxPC-3 cell
suspension (B0.5ml; containing approximately 210
6 cells) was
injected subcutaneously into the left flank of 6-week-old male
severe combined immunodeficient mice. After 4 weeks, the
tumours became obviously visible. Five groups of three tumour-
bearing mice were treated with a single dose of dasatinib
(50mgkg
1) or vehicle control (80mM sodium citrate/citric acid
buffer, pH 3.0) by oral gavage, and killed at 2, 4, 8, and 24h. Each
tumour was rapidly dissected from the surrounding tissues and cut
into pieces that were snap frozen in liquid nitrogen, fixed in
formalin for 24h then paraffin-embedded, or homogenised in 1ml
lysis buffer for western blot and immunoprecipitation.
RESULTS
EphA2 receptor tyrosine kinase activity is inhibited
directly by dasatinib
To determine whether the EphA2 receptor tyrosine kinase activity
is inhibited by dasatinib directly or whether the ability of dasatinib
to suppress EphA2 activity is an indirect effect of Src inhibition, we
performed in vitro autophosphorylation assays. HEK-293 cells
expressing EphA2 were immunoprecipitated with anti-EphA2
antibody and kinase assays were performed in the presence of
increasing amounts of dasatinib. Reduced autophosphorylation
was observed in a dose-dependent manner following addition of
dasatinib. Interestingly, dasatinib was also found to inhibit EphB2
directly at similar concentrations (Figure 1).
In vitro anti-tumour activity of dasatinib
As shown in Figure 2A, there was a dose-dependent decrease in cell
numbers following 48h treatment with dasatinib in all three cell
lines, with MIA PaCa-2 and BxPC-3 showing greater sensitivity
than PANC-1. This was associated with a corresponding decrease
in the percentages of cells in S phase, as shown in Figure 2B.
EphA2 activation affects downstream signalling
In all three pancreatic cancer cell lines, low basal levels of EphA2
tyrosine phosphorylation were detected in the absence of ligand,
and these showed large increases following ligand stimulation
(Figure 3A). As revealed by immunoblotting of total cell lysates
with a phosphotyrosine antibody (Figure 3B), the tyrosine
phosphorylation of several cellular proteins was significantly
induced following ephrinA1-Fc stimulation. We also probed these
lysates with phospho-specific antibodies to a number of cellular
signalling proteins. BxPC-3 cells showed increased Src phosphory-
lation at Tyr 416 compared with PANC-1 and MIA PaCa-2 cells
and we did not observe obvious responses upon ligand binding in
BxPC-3 PANC-1 MIA PaCa-2
−
−− −
−−− −− +++ + + −−−−−−+ + +++ −−−−−−+++++ Dasatinib
Ephrin A1-Fc 5′ 20′ 45′60′ 5′ 20′ 45′ 60′ −− −− 5′ 20′45′ 60′ 5′ 20′ 45′ 60′ −− 5′ 20′ 45′ 60′ 5′ 20′ 45′ 60′
IP:IgG IP:anti-EphA2
Blot:
a: P-Tyr-100
P-Tyr-100
p-Src(Tyr416)
b: P-Tyr-100
c: EphA2
t-Src
t-FAK
t-FAK
t-Akt
p-FAK(Tyr576/577)
p-FAK(Tyr925)
p-Paxillin(Tyr118)
t-Paxillin
p-Akt (Ser473)
p-ERK1/2
t-ERK1/2
t-STAT3
t-STAT3
p-STAT3(Ser727)
p-STAT3(Tyr705)
Figure 3 Inhibition of EphA2 receptor tyrosine kinase signalling in pancreatic cancer cell lines. Around 90% confluent serum-starved BxPC-3, PANC-1 and
MIA PaCa-2 cells were pretreated with or without 200nM dasatinib for 2h prior to 2mgml
1 ephrinA1-Fc stimulation for the indicated periods of time. Cells
were harvested at various time points. (A) Cell lysates were immunoprecipitated with anti-EphA2 antibody, analysed by phosphotyrosine (P-Tyr-100) and
EphA2 immunoblots. The same membrane was exposed for 45s (a) and then 10min (b) using ECL Plus. EphA2 reprobing (c) served as the loading control.
(B) Cell lysates were analysed by western blot using antibodies directed against phosphotyrosine (P-Tyr-100), p-Src (Tyr 416), Src, p-FAK (Tyr 576/577,
Tyr 925), FAK, p-Paxillin (Tyr 118), Paxillin, p-Akt (Ser 473), Akt, p-ERK1/2 (Thr 202/Tyr 204), ERK1/2, p-STAT3 (Ser 727, Tyr 705), STAT3.
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sthese cells. In contrast, Src and focal adhesion kinase (FAK)
showed transient dephosphorylation in PANC-1 and MIA PaCa-2
cells, consistent with previous reports (Miao et al, 2000). However,
paxillin, a downstream substrate of FAK, showed no obvious
responses to EphA2 activation in any of the three cell lines.
Interestingly, our data also showed that Akt phosphorylation at Ser
473 was increased following ligand stimulation. EphA2 activation
inhibited p44/42 mitogen-activated protein kinase (MAPK)
phosphorylation at Thr 202/Tyr 204 (phosphorylated extracellular
signal-regulated kinase, p-ERK1/2) in BxPC-3, yet p-ERK1/2 level
was increased at the 20min ephrinA1-Fc-binding time point in
PANC-1 and MIA PaCa-2. Moreover, we observed that signal
transducer and activator of transcription 3 (STAT3) phosphoryla-
tion at Tyr 705 was increased upon ligand binding in BxPC-3, but
this was much less evident in PANC-1 and MIA PaCa-2 cells.
Collectively, stimulation with ligand produced rapid increases of
EphA2 phosphorylation, although the effects of EphA2 activation
on downstream signalling differed among the pancreatic cancer
cell lines. As shown in Supplementary Figure 1, neither ephrinA1
nor EphB2 were detected at significant amounts in any of the three
cell lines.
Inhibition of Src by dasatinib
Consistent with the known effect of dasatinib on Src (Serrels et al,
2006; Shor et al, 2007), Src phosphorylation at Tyr 416 and FAK
phosphorylation at the Src-dependent sites (Tyr 576/577, Tyr 925)
were dramatically decreased with the pretreatment of dasatinib in
all three cell lines as shown in Figure 3B, and this inhibition
persisted during 24h continuous dasatinib treatment (not shown).
Paxillin phosphorylation at Tyr 118 was incompletely inhibited
by dasatinib. As shown in Figure 4, Src, FAK and Paxillin
phosphorylations were inhibited by dasatinib in a dose-dependent
manner, with or without ephrinA1-Fc ligand stimulation,
and similar effects were seen with the well-characterised Src
inhibitor PP2.
Inhibition of EphA2 by dasatinib
Pretreatment with dasatinib inhibited the low levels of constitutive
EphA2 tyrosine phosphorylation, as well as ligand-induced
activation in all three cell lines (Figure 3A). Inhibition of EphA2
tyrosine phosphorylation was dose-dependent and the IC50 was
similar to that for p-Src. In contrast, PP2 exhibited minimal
inhibition of EphA2 tyrosine phosphorylation in BxPC-3 cells
except at the highest concentration tested (20mM) (Figure 4).
Effects of dasatinib on ephrinA1-Fc stimulation
We next examined the effects of dasatinib on the activation
of downstream signalling in response to ephrinA1-Fc stimulation.
In the absence of ligand, treatment with dasatinib partially
inhibited Akt phosphorylation at Ser 473, ERK phosphorylation
at Thr 202/Tyr 204, and STAT3 phosphorylation at Ser 727 but not
Tyr 705 in all three cell lines (Figure 3B). Unexpectedly,
pretreatment with dasatinib at concentrations that strongly
inhibited EphA2 tyrosine phosphorylation failed to suppress
completely ligand-induced activation of Akt and ERK1/2 in all
three cell lines, and also the activation of STAT3 Tyr 705 that
occurred in BxPC-3 cells.
Dasatinib inhibits ligand-induced EphA2 internalisation
and degradation
Previous work has shown that ligand-binding results in the
internalisation and proteasomal degradation of EphA2, which is
Cbl-dependent (Walker-Daniels et al, 2002; Wang et al, 2002).
Subconfluent BxPC-3, PANC-1 and MIA PaCa-2 cells were
pretreated with solvent or 200nM dasatinib for 2h, then stimulated
with 2mgml
1 ephrinA1-Fc for 30min. In the absence of dasatinib,
a large increase in EphA2 association with Cbl was observed upon
ligand stimulation, concordant with the increased level of EphA2
autophosphorylation. As shown in Figure 5A, this effect was
strongly inhibited by dasatinib in all three cell lines. We also
observed that although there was a pronounced decrease in the
total protein levels of EphA2 3h following ligand stimulation,
consistent proteasomal degradation of the receptor, this effect was
diminished in the presence of dasatinib (Figure 5B). Furthermore,
using confocal microscopy, we observed that the subcellular
distribution of EphA2 showed internalisation followed by degrada-
tion after exposure to ephrinA1-Fc, whereas the cell surface
distribution of EphA2 was maintained with dasatinib pretreatment
(Figure 5C).
PP2
Dasatinib
Ephrin A1-Fc
Blot:
P-Tyr-100
EphA2
EphA2
P-Tyr-100
P-Scr(Tyr416)
IP: IgG IP: anti-EphA2
25 nM
50 nM
100 nM
200 nM
25 nM
50 nM
100 nM
200 nM 20 M
20 M
-Tubulin
t-Src
t-FAK
t-FAK
p-Paxillin(Tyr118)
t-Paxillin
t-Akt
p-FAK(Tyr576/577)
p-FAK(Tyr925)
p-Akt (Ser473)
p-STAT3(Ser727)
p-STAT3(Tyr705)
t-STAT3
t-STAT3
p-ERK1/2
t-ERK1/2
−
−
−−
−
−−
−−
−−−
− −
−
−− −− −
− −
− + + + + + +
Figure 4 Inhibition of EphA2 receptor tyrosine kinase is dose-
dependent. Around 90% confluent serum-starved BxPC-3 cells were
pretreated with the indicated concentration of dasatinib or 20mM PP2 for
2h prior to 2mgml
1 ephrinA1-Fc stimulation for 5min. Cell lysates were
immunoprecipitated with anti-EphA2 antibody, analysed by phospho-
tyrosine (P-Tyr-100) and EphA2 immunoblots. The cell lysates were also
analysed by western blot using the indicated antibodies.
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Figure 5 Dasatinib inhibits ligand-induced EphA2 internalisation and degradation. Approximately 90% confluent BxPC-3, PANC-1 and MIA PaCa-2 cells
were pretreated with 200nM dasatinib for 2h prior to 2mgml
1 ephrinA1-Fc stimulation. (A) Cell lysates were immunoprecipitated with anti-Cbl or anti-
EphA2 antibody 30min following ligand stimulation, and analysed by EphA2, phosphotyrosine (P-Tyr-100) or Cbl immunoblots. Cell lysates were also
analysed by western blot using anti-EphA2 or anti-Cbl antibody. a-Tubulin served as the loading control. (B) Cell lysates probed for EphA2 3h following
ligand activation. Densitometric data (fold change) are shown, normalised to a-tubulin. (C) The subcellular distribution of EphA2 30min following ligand
activation was evaluated using confocal microscopy. Contrast enhancement was applied uniformly to all panels.
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sInhibition of EphA2 receptor tyrosine kinase signalling in
BxPC-3 xenografts
BxPC-3 cells are the most responsive to dasatinib in vitro among
three pancreatic cell lines, and therefore selected for the in vivo
experiments. BxPC-3 tumour-bearing mice were treated with a
single dose of 50mgkg
1 dasatinib and killed at various time
points. As shown in Figure 6, EphA2 tyrosine phosphorylation was
readily detectable in the xenografts. This was partially inhibited
after 2 and 4h of dasatinib administration, similar to our results
in vitro, but at the 8h time point EphA2 phosphorylation was
increased above the baseline. Phosphotyrosine proteins were
decreased following dasatinib administration, but not to the extent
seen in the in vitro studies. Src and FAK dephosphorylation
occurred after 2 and 4h of dasatinib administration as expected,
and phosphorylation gradually recovered to pretreatment at
24h, consistent with the pharmacokinetics of this compound
(Lombardo et al, 2004). These results show that in addition to Src,
EphA2 autophosphorylation is inhibited by dasatinib in vivo.
DISCUSSION
Our study focused on the inhibition of EphA2 receptor tyrosine
kinase activity by dasatinib in pancreatic cancer. Although
previous studies have demonstrated that dasatinib suppresses cell
adhesion, migration, and invasion, and has potential as a
therapeutic agent for metastatic cancers through Src inhibition
(Johnson et al, 2005; Trevino et al, 2006; Shor et al, 2007), it seems
that not all of its biological and molecular effects are due to Src
inhibition (Johnson et al, 2005). As Src has been suggested to be
involved in the activation of Eph receptors (Kno ¨ll and Drescher,
2004; Landen et al, 2006), we tested for direct inhibitory effect of
dasatinib on Eph receptors using an in vitro kinase assay. The
results show that dasatinib inhibits EphA2 directly, which is
consistent with a recent study which reported that dasatinib has an
IC50 of 17nmoll
1 for EphA2 (Huang et al, 2007). Interestingly,
dasatinib was also found to inhibit EphB2 directly at similar
concentrations, suggesting that this agent is a more general Eph
receptor inhibitor as has been suggested recently by others
(Bantscheff et al, 2007; Rix et al, 2007). This is potentially
important as distinct biological effects have been reported for the
different Eph receptors. For example, EphB2 activity is believed to
have a function in suppressing tumour progression and metastasis
(Huusko et al, 2004; Batlle et al, 2005).
In this report, we detected low basal levels of EphA2 tyrosine
phosphorylation in BxPC-3, PANC-1 and MIA PaCa-2 pancreatic
cancer cell lines, and these were further enhanced following ligand
stimulation. But the influence of Eph/ephrin activation on cell
behaviour differs depending on the cell type (Kullander and Klein,
2002). Src and FAK showed transient dephosphorylation following
ligand stimulation in PANC-1 and MIA PaCa-2 cells but not in
BxPC-3 cells, consistent with previous studies (Miao et al, 2000;
Duxbury et al, 2004), indicating that EphA2 is constitutively
associated with Src and FAK, and may have an important function
in regulating their functions. In contrast, paxillin, a downstream
substrate of FAK, showed no obvious responses to EphA2
activation in all three cell lines.
Although Src can activate Akt directly (Jiang and Qiu, 2003) and
as well affect Ras-MAPK pathway (Olayioye et al, 2001), activation
of the EphA2 kinase has been shown to stimulate the MAPK
pathway (Pratt and Kinch, 2002) and phosphoinositide 3 kinase
pathway (Pandey et al, 1994). In contrast, others have shown that
activated EphA2 downregulates the Ras-MAPK pathway (Miao
et al, 2001). A recent study has demonstrated that EphA2 is a direct
transcriptional target of the Ras-Raf-MAPK pathway, and ligand-
stimulated EphA2 attenuates the growth factor-induced activation
of this pathway. EphA2 signalling contributes to a feedback loop
that regulates Ras activity in a ligand-dependent manner (Macrae
et al, 2005). Our results show activation of EphA2 kinase
stimulates Akt in all three cell lines. Furthermore, EphA2
activation inhibits ERK phosphorylation in BxPC-3 cells, whereas
producing increased ERK phosphorylation in PANC-1 and MIA
PaCa-2 cells. The explanation for this is not clear, although it
should be noted that BxPC-3 cells possess a wild-type K-Ras,
whereas this is mutant in PANC-1 and MIA PaCa-2.
STAT3 is a key signalling molecule for many cytokines and
growth factor receptors. Transcriptional activation seems to be
regulated by phosphorylation at Ser 727 through the MAPK or
mammalian target of rapamycin (mTOR) pathway (Yokogami
et al, 2000; Kanai et al, 2003). Although activation of STAT3 is
linked to persistent activity of tyrosine kinases, including Src
(Yeatman, 2004), STAT3 phosphorylation at Tyr 705, in response
to cytokine stimulation, is generally mediated by Janus-activated
kinase 1 (Ihle, 1995). Interestingly, we found that in BxPC-3 cells,
STAT3 phosphorylation at Ser 727 was inhibited by dasatinib but
unresponsive to ligand stimulation, whereas Tyr 705 was increased
following ephrinA1-Fc-binding and this effect was not inhibited by
dasatinib. As reported previously (Johnson et al, 2005, 2007), the
activation of STAT3 may be a compensatory effect that suppresses
the pro-apoptotic or anti-proliferative effects of dasatinib.
Dasatinib strongly inhibited EphA2 tyrosine phosphorylation of
EphA2 at dose levels similar to those that inhibited Src in all three
0 h 2 h 4 h 8 h 24 h
12 31 23123 123123
IP:anti-EphA2
Blot:
P-Tyr-100
EphA2
EphA2
-Tubulin
P-Tyr-100
p-Src(Tyr416)
p-FAK(Tyr576/577)
p-FAK(Tyr925)
p-Paxillin(Tyr118)
t-Paxillin
t-Src
t-FAK
t-FAK
p-Akt (Ser473)
t-Akt
p-Erk1/2
t-Erk1/2
p-STAT3(Ser727)
p-STAT3(Tyr705)
t-STAT3
t-STAT3
Figure 6 Inhibition of EphA2 receptor tyrosine kinase signalling in BxPC-
3 xenografts. Mice bearing BxPC-3 xenografts were treated with single
dose of 50mgkg
1 dasatinib or vehicle control for the indicated periods of
time. The zero time points are drug vehicle controls. Tumour lysates were
immunoprecipitated with anti-EphA2 antibody, analysed by phosphotyr-
osine (P-Tyr-100) and EphA2 immunoblots. The tumour lysates were also
analysed by western blot using the indicated antibodies.
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scell lines. However, as seen in Figure 2C, pronounced increases in
Akt and ERK activation occurred following ligand-induced
stimulation in the presence of dasatinib, whereas this was inhibited
by LY294002 and U0126, respectively, as expected (data not
shown). This contrasts with an extensive literature documenting
that small molecule inhibitors of other RTKs such as epidermal
growth factor receptor strongly inhibit ligand-induced activation
of ERK and Akt. The explanation for this effect is not clear.
Possibly sufficient activation of EphA2 (or perhaps a different
ephrinA1-responsive receptor) persists to affect downstream
signalling in the presence of dasatinib. Alternatively, higher-order
clustering through the STERILE a-MOTIF (SAM) domain or the
PDZ recognition motif might regulate ligand-stimulated signalling
events (Kullander and Klein, 2002) independent of tyrosine kinase
activity, and therefore insensitive to dasatinib.
Cell–cell contacts promote ligand binding, and ligand binding
induces so-called ‘forward signalling’ mostly through phospho-
tyrosine-mediated pathways (Kullander and Klein, 2002).
Upon ligand stimulation, EphA2 aggregates at the cell surface
and becomes tyrosine-phosphorylated, which promotes the
formation of a protein complex with the c-Cbl adapter protein
(Walker-Daniels et al, 2002). The complex of EphA2 and Cbl is
then internalised into early endosomes, where EphA2 is subse-
quently degraded through proteosomal and lysosomal pathways.
Exposure to ligand mimetics (ephrinA1-Fc) has been shown trigger
rapid EphA2 phosphorylation and receptor downregulation in
MDA-MB-231 breast (Zantek et al, 1999; Kiewlich et al, 2006) and
PC-3 prostate (Miao et al, 2000) cancer cells. We observed that
dasatinib inhibited ligand-induced Cbl binding and the inter-
nalisation and degradation of EphA2, suggesting that these are
dependent on kinase activity as has also been shown for kinase-
dead Eph receptors (Zimmer et al, 2003). We suggest that through
the inhibition of ligand-induced EphA2 degradation, dasatinib
might act to stabilise receptor/ligand binding, thereby promoting
adhesive rather than repulsive interactions, and suppressing
tumour invasiveness.
Preliminary experiments showed that treatment with dasatinib
results in a transient decrease of EphA2 phosphorylation in BxPC-
3 xenografts, indicating that this compound can modulate EphA2
at doses that are achievable in vivo. Dasatinib might therefore have
activity in pancreatic cancer because of EphA2 inhibition, in
addition to its effects on Src.
EphA2 is overexpressed in a number of human cancers,
including pancreatic cancer, and this is associated with poor
prognosis. Various strategies have been proposed to target
EphA2 in cancer, including the use of monoclonal antibodies
directed at EphA2 surface antigens and RNAi to EphA2
(Carles-Kinch et al, 2002; Landen et al, 2005). Although it remains
unclear if the activation of EphA2 tyrosine kinase is necessary for
its role in cancer progression, our results suggest that more
selective small molecule inhibitors of EphA2 might also have
clinical value.
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